Circassia Inc. Significantly Expands Reach of NIOX® FeNO Asthma Testing and Management Device with National Primary Care Distribution Agreements
MORRISVILLE, NC, April 26, 2022–(BUSINESS WIRE)–Circassia Inc. today announced that it has successfully engaged with major national primary care commercial partners to expand distribution of NIOX VERO®, its FeNO test device to United States. FeNO (fractionated exhaled nitric oxide) is used to assess airway inflammation, one of the key hallmarks of asthma. NIOX VERO® quickly and accurately measures FeNO levels in a single breath, at the point of care.
Circassia’s NIOX® products are used to improve outcomes in asthma patients and are indicated in the United States for use in persons 7 years of age and older. NIOX® technology is based on the discovery that patients with type 2 airway inflammation (formerly known as allergic or eosinophilic inflammation) typically have elevated levels of nitric oxide in their exhaled breath. Corticosteroid therapy has been shown to reduce FeNO levels. Research has shown that up to 84% of asthma patients suffer from type 2 airway inflammation, which is particularly associated with exacerbations. By measuring the concentration of FeNO, NIOX® enables clinicians to assess airway inflammation in asthma patients, aid in diagnosis and guide treatment to reduce exacerbations.
“NIOX® is the gold standard FeNO testing device and an accurate, reliable and simple technology trusted by thousands of healthcare professionals to help manage their patients’ asthma. Moving forward with a national distribution model, we are working toward our goal of ensuring the millions of asthma patients in the United States have access to this important device,” said Jeff Hill, Regional Vice President, Americas, Circassia.
According to the Centers for Disease Control and Prevention (CDC), approximately 25 million Americans live with asthma. Although airway inflammation is a key feature of asthma, it is not routinely measured and misdiagnosis using traditional methods is not uncommon. However, asthma is seven times more likely when FeNO levels are high.
Many asthma patients remain symptomatic despite treatment and are at increased risk of exacerbations. The consequences of poorly controlled asthma can be serious. About half of patients report having had an exacerbation in the last 12 months; exacerbations also account for 1,000 deaths per day worldwide. Optimizing therapy and treatment adherence with the FeNO test has been shown to reduce exacerbations by up to 50%. The non-invasive and rapid test results in more accurate asthma diagnosis and better patient care.
For these reasons, the FeNO test is supported by recent clinical practice guidelines published by the American Thoracic Society and the National Institutes of Health Asthma Guidelines. NIOX® is the leading FeNO test device in the United States and is available nationwide.
Our ambition is to improve the quality of life of millions of people suffering from asthma. Circassia is a medical device company focused on point-of-care asthma diagnosis and management. Our market-leading NIOX® products are used by physicians around the world to improve the diagnosis and management of asthma and by leading research organizations conducting clinical studies for pharmaceutical companies. Currently, Circassia provides products and services in over 50 countries. For more information, visit www.niox.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220426005163/en/
Rebecca Novak Tibbitt